GEN-MKT-18-7897-A
Feb 6, 2019 | Blogs, Forensic | 0 comments
Drug testing is a moving target. As novel psychoactive substances (NPS) rapidly emerge as a new class of designer stimulants (DS), global use has reached an all-time high over the last decade. Supposedly ‘legal’ alternatives to internationally controlled drugs, these compounds are typically manufactured ‘underground’ in unregulated laboratories by teams that are a step ahead of regulators. By simply altering the concoction of chemicals, the drugs slide under permissible legal radars.
With NPS-related deaths on the rise, the time it takes to detect these metabolites in forensic samples is critical. Clearly, there is a greater need for new technologies and methodologies to detect new substances and take an appropriate course of action to save lives.
I Don’t Know What I’m Looking for (But I’ll Know When I Have Found It)Trying to look for that “unknown” in a complex biological sample can be harder than finding a disguised fugitive in Grand Central Station at rush hour! It seems like an impossible task. The fast-paced nature of the market combined with widespread availability of an increasing number of substances is frightening. In fact, at the dawn of the millennium, the UN Office on Drugs and Crime (UNODC) listed only a handful of NPS. By 2008 the number was up to 26. Now more than 560 NPS are currently being monitored by the European Monitoring Centre for Drugs and Drug Addiction, with 100 new agents identified in 2015 alone.
Traditional drug screening tends to take a two-prong approach:
Where Unknown Compounds Can Hide, We Can FindIt seems that identifying the unknown in the evolving designer drug market, knowns are not that simple. Fret not! High-Resolution Accurate Mass Spectrometry (HRMS) innovation such as the SCIEX X500R QTOF system coupled with a detailed toxicology screening method for 664 forensic compounds can do the job.
The good news? There’s a concise and comprehensive way to screen for unknown substances in your forensic evidence. This technote shows how our HRMS system powered by SCIEX OS Software work together. Discover a single-injection method for screening 664 most up-to-date forensic compounds, with library searching to automate and confidently establish the identification of unknowns in an efficient, all-in-one workflow.
Read the tech note today by filling out the form on your right and downloading our Forensics Compendium.
Ultra‑low reporting limits, expanding target lists, and the constant risk of background contamination mean that even small missteps before injection can compromise data integrity. PFAS can be introduced at nearly every stage of prep, from sampling containers and PPE to SPE cartridges, filters, solvents, and lab consumables, making contamination control as critical as analyte recovery.
In monoclonal antibody (mAb) development, assessment of purity and integrity of the protein in question is critical. CE‑SDS is the gold standard assay and is routinely run from analytical development through QC and lot release. It’s trusted because it consistently delivers quantitative, size‑based insight into purity and fragmentation, and it fits naturally into regulated environments.
In drug discovery and development, Metabolite Identification (Met ID) plays a critical role in understanding biotransformation pathways, ensuring safety, and meeting regulatory requirements. Advanced mass spectrometry techniques have revolutionized this process, particularly through electron-based fragmentation methods such as Electron Activated Dissociation (EAD) and Electron Transfer Dissociation (ETD). While both techniques leverage electron interactions to generate informative fragment ions, they differ significantly in mechanism, performance, and suitability for Met ID workflows.
Posted by
You must be logged in to post a comment.
Share this post with your network